Depressive disorders in women during the menopausal transition and menopause

Titchenko Yu.P.; Kruchinina E.V.; Ovchinnikova V.V.; Tsar’kova A.V.; Yarygina T.A.

doi:https://doi.org/10.17116/rosakush20252505141

Titchenko Yu.P.

V.I. Krasnopolsky Moscow Regional Research Institute of Obstetrics and Gynecology

ORCID: 0000-0003-4109-0471

Kruchinina E.V.

V.I. Krasnopolsky Moscow Regional Scientific Research Institute of Obstetrics and Gynecology

ORCID: 0000-0002-3628-0863

Ovchinnikova V.V.

V.I. Krasnopolsky Moscow Regional Scientific Research Institute of Obstetrics and Gynecology

ORCID: 0000-0002-6611-2510

Tsar’kova A.V.

V.I. Krasnopolsky Moscow Regional Scientific Research Institute of Obstetrics and Gynecology

ORCID: 0000-0001-7251-1182

Yarygina T.A.

V.I. Krasnopolsky Moscow Regional Research Institute of Obstetrics and Gynecology

ORCID: 0000-0001-6140-1930

Depressive disorders in women during the menopausal transition and menopause

Authors:

Titchenko Yu.P., Kruchinina E.V., Ovchinnikova V.V., Tsar’kova A.V., Yarygina T.A.

More about the authors

Journal: Russian Bulletin of Obstetrician-Gynecologist. 2025;25(5): 41‑46

DOI: 10.17116/rosakush20252505141

Read: 172 times

Contact the author

Table of contents

To cite this article:

Titchenko YuP, Kruchinina EV, Ovchinnikova VV, Tsar’kova AV, Yarygina TA. Depressive disorders in women during the menopausal transition and menopause. Russian Bulletin of Obstetrician-Gynecologist. 2025;25(5):41‑46. (In Russ.)
https://doi.org/10.17116/rosakush20252505141

Подписка 2026 Российский вестник акушера-гинеколога (Russian Bulletin of Obstetrician-Gynecologist)

Использование инфографики авторами научных работ

Recommended articles:

Evaluation of the effectiveness of hormone therapy in patients with premature ovarian insufficiency. Russian Bulletin of Obstetrician-Gynecologist. 2025;(4):86-93

Transcranial magnetic stimulation (rTMS) in the treatment of depressive disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):55-59

Awareness of women about the prevention and correction of climacteric disorders. Russian Journal of Preventive Medicine. 2025;(1):57-62

Assessment of the effect of menopause symptoms on women’s quality of life and their attitude to the manifestations of menopause and menopausal hormone therapy. Russian Journal of Human Reproduction. 2025;(3):84-91

Abstract:

The perimenopausal period and menopause are often accompanied by symptoms of depression, since a decrease in estrogen levels causes the decline of reproductive function, emotional disorders, vasomotor symptoms, and genitourinary menopausal syndrome. Since the occurrence of disorders in the psycho-emotional sphere is due to the direct genomic effect of hypoestrogenism, hormone replacement therapy remains the most effective treatment method for vasomotor manifestations. The appointment of antidepressants, neuroleptics, antiepileptic drugs, and anxiolytics allows for a sustained effect in the emotional sphere, improving both the general condition and mental status of women during menopausal transition and menopause.

Keywords:

depressive disorders

menopause

hormone replacement therapy

Authors:

Titchenko Yu.P.

V.I. Krasnopolsky Moscow Regional Research Institute of Obstetrics and Gynecology

ORCID: 0000-0003-4109-0471

Kruchinina E.V.

V.I. Krasnopolsky Moscow Regional Scientific Research Institute of Obstetrics and Gynecology

ORCID: 0000-0002-3628-0863

Ovchinnikova V.V.

V.I. Krasnopolsky Moscow Regional Scientific Research Institute of Obstetrics and Gynecology

ORCID: 0000-0002-6611-2510

Tsar’kova A.V.

V.I. Krasnopolsky Moscow Regional Scientific Research Institute of Obstetrics and Gynecology

ORCID: 0000-0001-7251-1182

Yarygina T.A.

V.I. Krasnopolsky Moscow Regional Research Institute of Obstetrics and Gynecology

ORCID: 0000-0001-6140-1930

Received:

07.11.2024

Accepted:

02.12.2024

Close metadata

References:

Kostroma YaV, Belyaeva EN, Khazova EL, Kuznetsova LV, Zazerskaya IE. Assessment of the severity of climacteric syndrome and features of psycho-emotional status. Zhurnal akusherstva i zhenskikh boleznei. 2019;68:1:13-20. (In Russ.).
Akhmedova AA, Gorobets LN. Modern concepts of clinical-psychopathological and neuroendocrine features of depressions of menopausal transition and early postmenopause. Part 1. Sotsial’naya i klinicheskaya psikhiatriya. 2021;31:4:80-87. (In Russ.).
Maki PM, Kornstein SG, Joffe H, Bromberger JT, Freeman EW, Athappilly G, Bobo WV, Rubin LH, Koleva HK, Cohen LS, Soares CN. Guidelines for the Evaluation and Treatment of Perimenopausal Depression: Summary and Recommendations J Womens Health (Larchmt). 2019;28:2:117-134.
Schiller CE, Johnson SL, Adate AC, Schmidt PJ, Rubinowet DR. Reproductive Steroid Regulation of Mood and Behavior. Compr Physiol. 2016;6:3:1135-1160.
Li RX, Ma M, Xiao XR, Xu Y, Chen X, Li B. Perimenopausal syndrome and mood disorders in perimenopause: prevalence, severity, relationships, and risk factors. Medicine (Baltimore). 2016; 95:32:e4466.
Mazo GE, Ganzenko MA. Depression in women during the menopausal transition. Psikhiatriya i psikhofarmakoterapiya (zhurnal im. P.B. Gannushkina). 2016;18:6:30-36. (In Russ.).
Lebedev DA, Chernositov FV, Botasheva TL. Features of the psychological status of perimenopausal women with signs of climacteric syndrome. Russian Psychological Journal. 2017;14#4:121-137. (In Russ.).
Bromberger JT, Schott L, Kravitz HM, Joffe H. Risk factors for major depression during midlife among a community sample of women with and without prior major depression: are they the same or different. Psychol Med. 2015;45:1653-1664.
Freman EW, Sammel MD, Lui L, Gracia CR, Nelson DB, Lori Hollander L. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry. 2004;61:62-70.
Georgakis MK, Thomopoulos TP, Diamantaras A-A. Association of age at menopause and duration of reproductive period with depression after menopause: A Systematic Review and meta-analysis. Jama Psychiatry. 2016;73:2:139-149.
Slopien R, Rozycka A, Slopien A, Pawlak M, Warenik-Szymankiewicz A, Sajdak S. The genetic background of climacteric symptoms in women during menopause. Clin Exper Obstet Gynecol. 2016;43:4:495-499. https://doi.org/10.12891/ceog2076.2016
Bokhan NA, Luk’yanova EV, Simutkin GG. Depressive disorders in women in climacteric age (review of foreign literature 2012-2016). Byulleten’ sibirskoi meditsiny. 2018;17:2:100-113. (In Russ.).
International Classification of Diseases of the 10th Revision (ICD-10). Available at: https://mkb-10.com.(InRuss.).
Maksimova A. From depression. The exit is near. Moscow: OOO “Mann, Ivanov & Ferber Publ”. 2020;352. (In Russ.).
Jurczak A, Szkup M, Wieder-Huszla S, Grzywacz A, Samochowiec A, Karakiewicz B. The assessment of the relationship between personality, the presence of the 5HTT and MAOA polymorphisms, and the severity of climacteric and depressive symptoms in postmenopausal women. Arcbives Womens Mental Health. 2015;18:4:613-621. https://doi.org/10.1007/s00737-015-0497-0
Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition: The Harvard study of moods and cycles. Arch Gen Psychiatry. 2006; 63:4:385-390.
Slopien R, Wender-Ozegowska E, Rogowiez-Frontezak A, Meczekalski B., Zozulinska-Ziolkiewiez D, Jaremek JD, Cano A, Chedraui P, Goulis, DG, Lopes P, Mishra G, Mueck A, Rees M, Senturk LM, Simoncini T, Stevenson JC, Stute P, Tuomikoski P, Paschou SA, Anagnostis P, Lambrinoudaki I. Menopause and diabetes: EMAS clinical guide. Maturitas. 2018;117:6-10.
Yureneva SV, Orlova YaA. Menopausal transition is a focus on early and effective reduction of cardiometabolic risks. Doctor.Ru. 2023; 22:5:40-48. (In Russ.).
Vinokurova EA, Gorodnicheva IE, Kiseleva MA. The effectiveness of menopausal hormone therapy in women with menstrual syndrome. Gynekologiya. 2020;19:1:38-41. (In Russ.).
Ulumbekova GE, Khudova IYu. Assessment of demographic, social and economic effects when taking menopausal hormone therapy. ORGZDRAV: news, opinions, training. Vestnik VShOUZ. 2020;6:4:23-53. (In Russ.).
Anagnostis P, Bitzer J, Cano A, Ceausu I, Chedraui P, Durmusoglu F, Erkkola R, Goulis DG. Menopause symptom management in women with dyslipidemias: an EMAS clinical guide. Maturitas. 2020;135:82-88.
Gass MLS, Maki P, Shifren JL, Schnatz PF, Kaunitz AM, Shapiro M, Sievert LL. NAMS support judicious use of systemic hormone therapy for women aged 65 years and older. Menopause. 2015;22:7:685-686.
Zaidieva YaZ. Menopausal hormone therapy and oncological risks of the reproductive system. Literature review. Meditsinskii alfavit. 2019;1-1:376:42-50. (In Russ.).
Oboskalova GA, Koval’ MV. The effect of menopausal hormone therapy on uterine fibroids in postmenopausal women. Ural’skii meditsinskii zhurnal. 2017;6:150:5-9. (In Russ.).
Roehm E.A. Reappraisal of Womens Health Initiative Estrogen-Alone Trial: long-term outcomes in women 50-59 years of age. Obstet Gynecol Int. 2015;2015:713295.
Karim R, Xu W, Kono N, Sriprasert I, Li Y, Yan M, Stanczyk FZ, Shoupe D, Mack WJ, Hodis HN. Effect of menopausal hormone therapy on arterial wall echomorfology: Resalts from the Early versus Late Intervention Trial with Estradiol (ELITE). Maturitas. 2022;162:15-22.
Hodis HN, Mack WJ, Hendersen VW, Shoupe D, Budoff MJ, Hwang-Levine J, Li Y, Feng M, L Dustin, N Kono, FZ Stanczyk, RH Selzer, SP Azen; ELITE Research Group. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374:13:1221-1231.
Dubrovina SO. Rational approach to hormone therapy in women over 40 years of age. Akusherstvo i ginekologiya. 2019;7:112-116. (In Russ.).
Sukhikh GT, Smetnik VP, Andreeva EN, Balan VE, Gavisova AA, Grigoryan OR, Ermakova EI, Zaidieva YaZ, Il’ina LM, Kasyan VN, Marchenko LA, Podzolkova NM, Rogovskaya SI, Smetnik AA, Chernukha GE, Yurneeva SV. Menopausal hormone therapy and the preservation of women’s health in adulthood. Russian Journal of Human Reproduction. 2018;24:56:727-756. (In Russ.).
Wierman ME Arlt W, Basson R, Davis SR, Miller KK, Murad MH, Rosner W, Santoroet N. Androgen therapy in women: A reappraisal: An Endocrine Socierty clinical practice guideline. J Clin Endocrinol Metab. 2014;99:10:3489-3510.
Baber RJ, Panay N, Fenton A; IMS Writing Group. 2016 IMS Recommendation on women’s midlife and menopause hormone therapy. Climacteric. 2016;19:2:109-150.
Balan VE, Tikhomirova EV. Menopausal hormone therapy with minimal risks. Meditsinskii alfavit. 2018;1-6:343:6-9. (In Russ.).
Yureneva SV, Dubrovina AV. The advantages of early/timely start of menopausal hormone therapy from the standpoint of the theory of euestrogens. Russian Bulletin of Obstetrician-Gynecologist. 2018;18:5:49-55. (In Russ.). https://doi.org/10.17116/rosakush20181805149
Kuznetsova IV. Menopausal symptoms and disorders in women: possibilities of alternative therapy. Akusherstvo i ginekologa: novosti, mneniya, obuchenie. 2019;7:1:85-91. (In Russ.).
Palinkas LA, Barret-Connor E. Estrogen use and depressive symptoms in postmenopausal women. Obstet Gynecol. 1992;80:1:30-36.
Hamoda H, Panay N, Pedder H, Arya R, Savvaset M. The British Menopause Society and Womens Health Concern 2020 recommend P. 181-209.ations on hormone replacement therapy in menopausal women. Post Reprod Health. 2020;26:4:181-204.
Gordon JL, Girdler SS, Meltzer-Brody SE, Stika CS, Thurston RC, Clark CT, Prairie BA. Ovarian hormone fluctuation neurosteroids and HPA axis dysregulation in perimenopausal depression: a novel heuristic model. Am J Psychiatry. 2015;172:227-336.
Cohen LS, Soares CN, Poitras JR, Prouty J, Alexande AB, Shifrenet JL. Short-term use of estradiol for depression in perimenopausal and postmenopausal women a preliminary report Am J Psychiatry. 2003;160:8:1519-1522.
Gava G, Orsili I, Alvisi S, Mancini I, Seracchioli R, Meriggiolaet MC. Cognition, mood and sleep in menopausal transition: The role of menopause hormone therapy. Medicina (Kaunas). 2019; 55:10:668.
Tyuvina NA, Balabanova VV, Voronina EO. Depression in women, manifesting during menopause. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;17:3:22-27. (In Russ.). https://doi.org/10.17116/jnevro20171173122-27
Lapochkina NP, Matasheva AV, Krupenina EA. Selective serotonin reuptake inhibitors in climacteric syndrome. Vestnik Ivanovskoi meditsinskoi akademii. 2015;20:4:34-38. (In Russ.).
Walecka-Kapica E, Chojnacki J, Stepien A, Wachowska-Kelly P, Klupińska G, Chojnacki C. Melatonin and female hormone secretion in postmenopausal overweight women. Intern J Mol Scie. 2015;16:1:1030-1042. https://doi.org/10.3390/ijms16011030
Gal’tsev EV, Kazenashev VV. Psychosociative discomfort in women with estrogen-conditioned urogenital disorders. Akusherstvo, ginekologiya i reproduktsiya. 2007;2:4-9. (In Russ.).
Blinov DV, Khazan PL, Mnatsakan’yan AL, Korabel’nikov DI, Safarov AT, Pavlova NV, Zakharova NS, Ponomarev DA, Petrenko DA. Early menopause and premature ovarian failure6: problems and prospects. Akusherstvo, ginekologiya i reproduktsiya. 2020;14:3:328-345.
Pizova NA, Pizov NA, Pizov AV. Perimenopausal period and mood disorders. Meditsinskii sovet. 2021;4:230-239. (In Russ.).
Schneider LS, Small GW, Hamilton SH, Bystritsky A, Nemeroff CB. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Am J Geriatr Psychiatry. 1997; 5:2:97-106.